Visceral Pain | A Drug Pipeline Analysis Report 2018 | Technavio
LONDON--(BUSINESS WIRE)--Aug 2, 2018--Technavio has announced their latest report on drug pipeline analysis for . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat visceral pain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180802005921/en/
Technavio has published a new report on the drug development pipeline for visceral pain, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Visceral pain: Market overview
Visceral pain is a type of nociceptive pain, which results from the activation of nociceptors in thoracic, pelvic, or abdominal viscera organs. Nociceptive pain is caused by an injury, physical pressure, or inflammation of some part of the body. The treatment of visceral pain includes analgesics, such as narcotics and NSAIDs, and pain modifiers such as tricyclic antidepressants and anticonvulsants.
According to a senior market research analyst at Technavio, “Visceral pain can be experienced in the trunk area of the body, including the abdominal part, pelvic organs, heart, and lungs, owing to inflammation. The pain is felt as generalized squeezing or aching in the body.”
Visceral pain: Segmentation analysis
This pipeline analysis report segments the visceral pain market based on therapies employed (monotherapy), RoA (oral), therapeutic modality (small molecule and monoclonal antibody), targets (CB-2 receptor, GABAB receptor, glutamate 2/3 receptor, homomeric hP2X3 and heteromeric hP2X2/3 receptor, KCNQ channel, mGlu7 receptor, NaV1.7 voltage-gated sodium ion channel, and P2X3 receptor), MoA (cannabinoid 2 receptor agonist, GABAB receptor allosteric modulator, glutamate 2/3 receptor agonist, homomeric hP2X3 and heteromeric hP2X2/3 receptor inhibitor, mGlu7 receptor allosteric modulator, NaV1.7 voltage-gated sodium ion channel antagonist, P2X3 receptor agonist, and sigma receptor agonist), geographical segmentation (US) and recruitment status (recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, more than 67% of the molecules that are being investigated for the treatment of visceral pain are small molecule.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180802005921/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH GENERAL HEALTH PHYSICAL THERAPY
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 08/02/2018 04:23 PM/DISC: 08/02/2018 04:23 PM